Trimetrexate efficacy and pharmacokinetics during treatment of refractory Pneumocystis carinii pneumonia in an infant with severe combined immunodeficiency disease.
Smit
M J
MJ
Department of Pediatrics, Sophia Children's Hospital, Rotterdam, The Netherlands.
De Groot
R
R
Van Dongen
J J
JJ
Van der Voort
E
E
Neijens
H J
HJ
Whitfield
L R
LR
D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004338:Drug Combinations / Q000493:pharmacokinetics / Q000627:therapeutic use; D005965:Glucuronates / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007223:Infant; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D010419:Pentamidine / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy*; D011799:Quinazolines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D012131:Respiratory Insufficiency / Q000150:complications; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D016597:Trimetrexate / Q000031:analogs & derivatives*
D000935:Antifungal Agents; D004338:Drug Combinations; D005965:Glucuronates; D011799:Quinazolines; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C056321:trimetrexate glucuronate; D002955:Leucovorin; D016597:Trimetrexate